Rationale, design and methods of the OSCAR study: Observational study on cognitive function and systolic blood pressure reduction in hypertensive patients

Fundamental and Clinical Pharmacology

Volumn 21, Issue 2, 2007, Pages 199-205

  Pathak, Atul ^a   Hanon, Olivier ^b   Negre Pages, Laurence ^a   Sevenier, Franck ^c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b Paris Descartes University   (France)

^c EVIDENCE Based Communication   (France)

Author keywords

Angiotensin II receptor antagonist; Cognitive function; Dementia; Eprosartan; Hypertension; Observational study

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; EPROSARTAN; HYDROCHLOROTHIAZIDE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; ETHNICITY; FEMALE; HUMAN; HYPERTENSION; MALE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHYSICIAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SCORING SYSTEM; SCREENING TEST; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN;

ACRYLATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTICENTER STUDIES; NEUROPSYCHOLOGICAL TESTS; OBSERVATION; PATIENT SELECTION; RECEPTOR, ANGIOTENSIN, TYPE 1; RESEARCH DESIGN; THIOPHENES;

EID: 33947616188     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2006.00465.x     Document Type: Article

References (38)

1. Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension (2003) 42 1206-1252.
2. Singh-Manoux A., Marmot M. High blood pressure was associated with cognitive function in middle-age in the Whitehall II study. J. Clin. Epidemiol. (2005) 58 1308-1315.
3. Skoog I., Lernfelt B., Landahl S. et al. 15-year longitudinal study of blood pressure and dementia. Lancet (1996) 347 1141-1145.
4. Birns J., Markus H., Kalra L. Blood pressure reduction for vascular risk. Is there a price to be paid? Stroke (2005) 36 1308-1313.
5. Swan G.E., Carmelli D., Larue A. Systolic blood pressure tracking over 25 and 30 years and cognitive performance in older adults. Stroke (1998) 29 2334-2340.
6. Walstein S.R., Giggey P.P., Thaver J.F., Zondermann A.B. Nonlinear relationships of blood pressure to cognitive function: the Baltimore Longitudinal Study of Aging. Hypertension (2005) 45 374-379.
7. van Boxtel M.P., Henskens L.H., Kroon A.A. et al. Ambulatory blood pressure, asymptomatic cerebrovascular damage and cognitive function in essential hypertension. J. Hum. Hypertens. (2006) 20 5-13.
8. Birns J., Kalra L. Blood pressure and vascular cognitive impairment: the debate continues. J. Hum. Hypertens. (2006) 20 1-3.
9. Amenta F., Mignini F., Rabbia F., Tomassoni D., Veglio F. Protective effect of antihypertensive treatment on cognitive function in essential hypertension: analysis of published data. J. Neurol. Sci. (2002) 203-204 147-151.
10. Hanon O., Pequignot R., Seux M.L. et al. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J. Hypertens. (2006) 24 2101-2107.
11. Qiu C., Winblad B., Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. (2005) 4 487-499.
12. Feigin V., Ratnasabapathy Y., Anderson C. Does blood pressure lowering treatment prevent dementia or cognitive decline in patients in patients with cardiovascular and cerebrovascular disease? J. Neurol. Sci. (2005) 229-30 151-155.
13. Tzourio C., Anderson C., Chapman N. et al. The PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med. (2003) 163 1069-1075.
14. Skoog I., Lithell H., Hansson L. et al. The SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am. J. Hypertens. (2005) 18 1052-1059.
15. Guo Z., Fratiglioni L., Zhu L., Fastbom J., Winblad B., Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch. Neurol. (1999) 56 991-996.
16. Murray M.D., Lane K.A., Gao S. et al. Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Arch. Intern. Med. (2002) 162 2090-2096.
17. Dufouil C., Chalmers J., Coskun O. et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation (2005) 112 1644-1650.
18. Van Dijk E.J., Breteler M.M., Schmidt R., Berger K., Nilsson L.G., Oudkerk M. for the CASCADE consortium. The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension (2004) 44 625-630.
19. Domeney A.M. Angiotensin converting enzyme inhibitors as potential cognitive enhancing agents. J. Psychiatry Neurosci. (1994) 19 46-50.
20. Arregui A., Perry E.K., Rossor M., Tomlinson B.E. Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas. J. Neurochem. (1982) 38 1490-1492.
21. Barnes J.M., Barnes N.M., Costall B. et al. Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition. Brain Res. (1990) 507 341-343.
22. Gard P.R. The role of angiotensin II in cognition and behaviour. Eur. J. Pharmacol. (2002) 438 1-14.
23. Tedesco M.A., Ratti G., Mennella S. et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am. J. Hypertens. (1999) 12 1130-1134.
24. Schrader J., Luders S., Kulschewski A. et al. MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke (2005) 36 1218-1226.
25. Ruilope L., Jager B., Prichard B. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press. (2001) 10 223-229.
26. Punzi H.A., Punzi C.F. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. J. Hum. Hypertens. (2004) 18 655-661.
27. Robins G.W., Scott L.J. Eprosartan: a review of its use in the management of hypertension. Drugs (2005) 65 2355-2377.
28. Folstein M.F., Folstein S.E., McHugh P.R. et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. (1975) 12 189-198.
29. Lithell H., Hansson L., Skoog I. et al. The SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. (2003) 21 875-886.
30. Fournier A., Messerli F.H., Achard J.M., Fernandez L. Cerebroprotection mediated by angiotensin II. A hypothesis supported by recent randomized clinical trials. J. Am. Coll. Cardiol. (2004) 43 1343-1347.
31. MacMahon S., Pete R., Cutler J. et al. Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 335 765-774.
32. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 335 827-838.
33. Mancia G. Prevention and treatment of stroke in patients with hypertension. Clin. Ther. (2004) 26 631-649.
34. Ferrari P., Wu C.J., Pham N.V., Ageev F., Hermosillo L.D., Esper R., for the RIAT trialists. Aim, design and methods of the 'reasons for not intensifying antihypertensive treatment' (R. IAT): an international registry in essential hypertension. J. Hum. Hypertens. (2006) 20 31-36.
35. Peters R., Beckett N., Nunes M., Fletcher A., Forette F., Bulpitt C. A substudy protocol of the hypertension in the very elderly trial assessing cognitive decline and dementia incidence (HYVET-COG): an ongoing randomised, double-blind, placebocontrolled trial. Drugs Aging (2006) 23 83-92.
36. Starr J.M., Whalley L.J., Deary I.J. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. J. Am. Geriatr. Soc. (1996) 44 411-415.
37. Starr J.M., Whalley L.J., Deary I.J. Differential cognitive outcomes in the Hypertensive Old People in Edinburgh study. J. Neurol. Sci. (2005) 229-230 103-107.
38. Muldoon M.F., Waldstein S.R., Ryan C.M. et al. Effects of six anti-hypertensive medications on cognitive performance. J. Hypertens. (2002) 20 1643-1652.